Valneva Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Valneva şirketinin kazançları yıllık ortalama -5.3% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 14.3% oranında artan oldu.

Anahtar bilgiler

-5.3%

Kazanç büyüme oranı

0.8%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	14.3%
Özkaynak getirisi	-3.4%
Net Marj	-4.7%
Sonraki Kazanç Güncellemesi	20 Mar 2025

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Valneva nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:VALN Gelir, gider ve kazançlar (EUR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	159	-7	96	0
30 Jun 24	156	-32	100	0
31 Mar 24	153	-24	101	0
31 Dec 23	154	-101	97	0
30 Sep 23	223	-113	90	0
30 Jun 23	426	-7	77	-52
31 Mar 23	373	-135	69	0
31 Dec 22	361	-143	58	0
30 Sep 22	439	73	61	0
30 Jun 22	304	-159	65	52
31 Mar 22	347	-72	64	0
31 Dec 21	348	-73	71	0
30 Sep 21	121	-248	60	0
30 Jun 21	110	-125	56	0
31 Mar 21	98	-91	50	0
31 Dec 20	110	-64	46	0
30 Sep 20	104	-62	46	0
30 Jun 20	120	-25	43	0
31 Mar 20	127	-8	44	0
31 Dec 19	126	-2	43	0
30 Sep 19	116	4	40	0
30 Jun 19	109	1	39	0
31 Mar 19	116	7	38	0
31 Dec 18	113	3	38	0
30 Sep 18	107	-7	38	0
30 Jun 18	110	-7	38	0
31 Mar 18	108	-8	35	0
31 Dec 17	105	-11	33	0
30 Sep 17	103	-11	33	0
30 Jun 17	100	-14	32	0
31 Mar 17	102	-46	32	0
31 Dec 16	98	-49	31	0
30 Sep 16	93	-63	29	0
30 Jun 16	96	-61	28	0
31 Mar 16	89	-35	27	0
31 Dec 15	83	-21	24	0
30 Sep 15	74	-16	20	0
30 Jun 15	65	-13	17	0
31 Mar 15	55	-9	15	0
31 Dec 14	42	-26	14	0
30 Sep 14	41	-21	13	0
30 Jun 14	43	-28	17	0
31 Mar 14	41	-29	17	0
31 Dec 13	36	-24	15	0

Kaliteli Kazançlar: VALN şu anda kârlı değil.

Büyüyen Kar Marjı: VALN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: VALN kârlı değildir ve zararlar son 5 yılda yılda 5.3% oranında artmıştır.

Büyüme Hızlandırma: VALN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: VALN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: VALN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -3.41% ) sahiptir.

Valneva Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Valneva SE to Report Q1, 2025 Results on May 07, 2025

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE to Report Q1, 2024 Results on May 07, 2024

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Recent updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Valneva SE to Report Q1, 2025 Results on May 07, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Valneva Se Provides Revenue Guidance for the Year 2023

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

Valneva seeking a partnership for next-gen COVID-19 vaccine

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva shows booster effect of COVID shot against AstraZeneca vaccine

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Valneva launches up to $75M at-the-market ADS offering program

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Valneva: Vaccine Business, Catalysts Ahead, And Pfizer's Lyme Love

Valneva agrees to cut COVID vaccine supplies to EU

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Valneva SE Announces Supervisory Board Member Appointments

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Valneva SE announced that it expects to receive €90.627232 million in funding from Pfizer Inc.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin